Aspirin for Hepatocellular Carcinoma Prevention in MASLD: How Far Are We Ready to Proceed?: Editorial on “Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis”

Aspirin has a long history, originating from its use as an analgesic and antipyretic in ancient civilizations

Authors

Institutions

Publication Details

Journal
Clinical and Molecular Hepatology
Published
2026-01-09
DOI
https://doi.org/10.3350/cmh.2025.1482
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Aspirin for Hepatocellular Carcinoma Prevention in MASLD: How Far Are We Ready to Proceed?: Editorial on “Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis”

Kang Mo Kim
Clinical and Molecular Hepatology
Hepatocellular Carcinoma Treatment and Prognosis
article

Aspirin for Hepatocellular Carcinoma Prevention in MASLD: How Far Are We Ready to Proceed?: Editorial on “Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis”

Kang Mo Kim
article en

Abstract

Aspirin has a long history, originating from its use as an analgesic and antipyretic in ancient civilizations

Clinical and Molecular Hepatology
Dong-A University (KR)
Openalex Percentile: Top 93%
Hepatocellular Carcinoma Treatment and Prognosis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Aspirin for Hepatocellular Carcinoma Prevention in MASLD: How Far Are We Ready to Proceed?: Editorial on “Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis” — Kang Mo Kim · Clinical and Molecular Hepatology (2026) | TGRS Research Map | TGRS